2025 Europe Antibody Library Technology Market Revenue Opportunities Report
Description
The 2025 Europe Antibody Library Technology Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Library Technology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the European Antibody Library Technology Market include argenx (Belgium/Netherlands), MorphoSys AG (Germany), Genmab A/S (Denmark), and Philogen S.p.A. (Italy). Argenx is a leader in antibody-based therapies focusing on autoimmune diseases and cancer, leveraging its proprietary Immunobody platform for targeted antibody fragments and holding a market cap near $39 billion. MorphoSys, a pioneer since 1992, developed proprietary antibody library platforms and maintains significant collaborations for therapeutic development despite recent valuation challenges. Genmab and Philogen are also key European players advancing antibody library technologies for novel therapeutic antibodies, especially in oncology and autoimmune treatments.
These companies operate amid a growing European market supported by advanced research infrastructure and increasing demand for targeted therapies. MorphoSys has embarked on a multi-year technology development to upgrade its antibody generation platform, reflecting innovation in the field. Likewise, Genmab uses combinatorial libraries for human monoclonal antibody discovery, contributing to Europe's competitive footprint. Philogen specializes in antibody-based therapeutics using synthetic libraries to develop precision medicines. Collectively, their efforts drive Europe’s focus on antibody therapies, addressing cancer, autoimmune, and infectious diseases through cutting-edge technologies like phage and yeast display.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Library Technology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the European Antibody Library Technology Market include argenx (Belgium/Netherlands), MorphoSys AG (Germany), Genmab A/S (Denmark), and Philogen S.p.A. (Italy). Argenx is a leader in antibody-based therapies focusing on autoimmune diseases and cancer, leveraging its proprietary Immunobody platform for targeted antibody fragments and holding a market cap near $39 billion. MorphoSys, a pioneer since 1992, developed proprietary antibody library platforms and maintains significant collaborations for therapeutic development despite recent valuation challenges. Genmab and Philogen are also key European players advancing antibody library technologies for novel therapeutic antibodies, especially in oncology and autoimmune treatments.
These companies operate amid a growing European market supported by advanced research infrastructure and increasing demand for targeted therapies. MorphoSys has embarked on a multi-year technology development to upgrade its antibody generation platform, reflecting innovation in the field. Likewise, Genmab uses combinatorial libraries for human monoclonal antibody discovery, contributing to Europe's competitive footprint. Philogen specializes in antibody-based therapeutics using synthetic libraries to develop precision medicines. Collectively, their efforts drive Europe’s focus on antibody therapies, addressing cancer, autoimmune, and infectious diseases through cutting-edge technologies like phage and yeast display.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
